Durable responses in acute lymphoblastic leukaemia with the use of FLT3 and IDH inhibitors.

Mednet Member

Hematology · University of Chicago

Regimens to consider with data for R/R T-ALL include: Nelarabine +/- chemotherapy. There are retrospective data to support adding nelarabine to a chemo backbone (Shimony et al., PMID 36508268 and Shimony et al., PMID 37389830). HMA + venetoclax (Pinton et al., PMID 37889114 and Cao et al., Blood 202...